Year: 2020
Type: review
Abstract: In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea.
Institutions: Yonsei University, Konkuk University, Konkuk University Medical Center, Yonsei University Health System, Daegu Catholic University, Daegu Catholic University Medical Center, Seoul National University Bundang Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Seoul National University, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Samsung Medical Center, Sungkyunkwan University, Hallym University Medical Center, Yeungnam University Medical Center, Yeungnam University College, Yeungnam University, Ewha Womans University, Ewha Womans University Seoul Hospital, Veterans Health Service Medical Center, Gachon University Gil Medical Center, Soonchunhyang University, Korea University Guro Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $500
OpenAlex ID: W3097163034